53. Sjogren syndrome
234 clinical trials,   270 drugs   (DrugBank: 85 drugs),   49 drug target genes,   174 drug target pathways

Searched query = "Sjogren syndrome", "Sjögren syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04397107
(ClinicalTrials.gov)
August 15, 20206/5/2020The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic DiseasesThe Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases (Systemic Lupus Erythematosus, Primary Sjögren Syndrome, Juvenile Idiopathic Arthritis)Systemic Lupus ErythematosusDrug: IL-2First Hospital of Jilin UniversityNULLRecruitingN/A17 YearsAll46N/AChina
2ChiCTR-INR-17011220
2017-04-242017-04-23The Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndromeThe Efficacy and Safety of Low Dose IL-2Therapy in Chinese patients with primary Sjogren's syndrome primary Sj?gren’s syndromeLl-2 group:IL-2 treatment; non IL-2 group:conventional treatment;the Second Hospital of Shanxi Medical UniversityNULLRecruitingBothLl-2 group:90; non IL-2 group:90;China
3NCT02464319
(ClinicalTrials.gov)
June 1, 201530/5/2015A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's SyndromeSafety and Efficiency Study of Low-dose IL-2 Treatment in Primary Sjögren's SyndromePrimary Sjögren's SyndromeDrug: hrIL-2 active;Drug: hrIL-2 placeboPeking University People's HospitalMonash University;Beijing ShuangLu Pharmaceutical Co., Ltd.Completed18 Years65 YearsAll60Phase 2China